Real world experience of GenXSync™ sirolimus eluting coronary stent system in patients with long coronary lesions: outcome of the GEL registry


  • Hiremath M. S. Department of Cardiology, Ruby Hall Clinic, Pune, Maharashtra, India
  • C. N. Makhale Department of Cardiology, Ruby Hall Clinic, Pune, Maharashtra, India
  • Abhishek Gorlawar Department of Radiology, Ravi Imaging, Jupitor Scan Centre, Mumbai, Maharashtra, India
  • Ashish Indani SME Medical Devices, Medical Writing, Tata Consultancy Services, Mumbai, Maharashtra, India
  • Poonam Bhutada Department of Research Methodology, Krishnamugdha Insititute of Advanced Learning and Research, Maharashtra, India
  • Murlidhar Bendale MIV Therapeutics, Surat, Gujarat, India



Angioplasty, Complex PCI, Genxsync, Long stent, Long lesion PCI, MIV therapeutics, Hybrid design stent, Percuteneous coronary intervention, PCI, Sirolimus eluting stent, Tata consultancy services


Background: The study aimed to assess the immediate (procedural outcome) and long- term clinical (Cumulative hierarchical MACE up to 2 years) and angiographic outcomes (late lumen loss at 8 months) in the patients undergoing angioplasty with at least one 40 mm GenXSync™ SES. (Indian Study Regulatory ID CTRI/2014/07/004783).

Methods: This single centre prospective study included 26 real-world coronary artery disease (CAD) patients with long and very long lesions (38 lesions, 48 stents). All patients were treated with one or more 40 mm GenxSync™ sirolimus eluting stent (SES). All the subjects were followed up for 2 years including angiographic follow-up at 8 months.  Angiography data was evaluated and reported by an independent angiographic core-lab.  Subset analyses were performed for all 40mm long stents and 40mm with small diameter stents.

Results: The procedural success was observed in 94%. The acute gain was 2.25±0.53mm in stent and 2.09±0.71mm in segment despite of long and complex lesions including CTO. At 2 years, there was only 1 (3.84%) MACE (binary restenosis at 8 months) and stent thrombosis. At 8 months late lumen loss was in-segment 0.15±0.30mm and in-stent 0.14±0.17mm (p = 0.06). The 40mm stents subset, revealed acute gain of 2.21±0.58mm in-stent and 2.01±0.74mm in-segment.  The late loss was 0.16± 0.31mm and 0.13±0.17mm in-stent and in-segment respectively. In 40mm stent with small diameter subset, the acute gain was 2.19±0.42mm in-stent and 1.69 ± 0.59mm in-segment and late lumen loss was 0.10±0.18mm in-segment and 0.13± 0.33mm in-stent.

Conclusions: The results of real world long lesions PCI revealed efficacy, safety and procedural success observed with GenXSync™ stent comparable to other reported studies.


Shiomi H, Yamaji K, Morimoto T, Shizuta S, Nakatsuma K, Higami H, et al. Very long-term (10 to 14 year) outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease in the bare-metal stent era. Circ Cardiovasc Interv. 2016;9(8):003365.

Li Y, Bhindi R, Khachigian LM. Recent developments in drug-eluting stents. J Mol Med. 2011;89:545-53.

Shetty R, Vivek G, Thakkar A. Experience with biodegradable polymer coated sirolimus-eluting coronary stent system in “real-life” percutaneous coronary intervention: 24-Month Data from the Manipal-S Registry. J Clin Diag Res. 2013;7(9):1959-63.

Seth A, Serruys PW, Lansky A. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. Euro Intervention. 2010;5(7):788-94.

Stone GW, Midei M, Newman W. For the SPIRIT III Investigators. randomized comparison of everolimus-eluting and paclitaxel-eluting stents; two-year clinical follow-up from the clinical evaluation of the xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation. 2009;119:680-6.

Windecker S, Serruys PW, Wandel S. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-73.

Ostojic MC, Perisic Z, Sagic D, Jung R, Zhang YL, Peart BJ, Betts R, Christians U. On behalf of the stealth PK investigators. The pharmacokinetics of biolimus a9 after elution from the bio matrix II stent in patients with coronary artery disease: The Stealth PK Study. European J Clinical Pharmacol. 2011;67(4):389-98.

Grube E. Safety and performance evaluation of biosensors biolimus A9™ eluting stent (BioMatrix™) STEALTH I: a 4-year safety follow-up, e-poster. 2008.

Chevalier B, Serruys PW, Silber S. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. Euro Intervention. 2007;2(4):426-34.

Dani S, Costa RA, Joshi H, Shah J, Pandya R, Virmani R, et al. First-in-human evaluation of the novel biomime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial. Euro Intervention. 2013;9(4):493-500.

Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res. 2013;99(2):353-63.

Itoh T, Fusazaki T, Kimura T, Oikawa H, Sasou S, Ishikawa Y, et al. Clinical and pathological characteristics of homogeneous and non-homogeneous tissue of in-stent restenosis visualized by optical coherence tomography. Coron Artery Dis. 2015;26(3):201-11.

13 - Kastrati, Adnan, Shpend Elezi, Josef Dirschinger, Martin Hadamitzky, Franz-Josef Neumann, and Albert Schömig. "Influence of lesion length on restenosis after coronary stent placement." The American journal of cardiology 83, no. 12 (1999): 1617-1622.

Schampaert E, Cohen EA, Schlüter M. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43(6):1110-5.

Fajadet J, William W, Gert L, Karl HK, Ormiston J, Münzel T, et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions clinical and angiographic results of the endeavor II trial. Circulation. 2006;114(8):798-806.

Stone, Gregg W, Ellis SG, Cox DA, Hermiller J, Shaughnessy O, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent the TAXUS-IV trial. Circulation. 2004;109(16):1942-7.






Original Research Articles